PARIS – Gleamer SAS said Radiology published compelling results from a study evaluating the performance of its artificial intelligence (AI) system Boneview, which helps radiologists and emergency doctors detect and localize fractures. This is the first study to evaluate the performance of AI-assisted health care professionals in locating bone fractures on all appendicular X-rays.
Immvira Group Co. presented positive phase I data for MVR-T3011 as an intratumoral administration (MVR-T3011 IT) at the 2021 American Society of Clinical Oncology annual meeting this month, drawing attention to oncolytic viruses developed by Chinese scientists.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biogen, Curevac, Harbour, Kancera, Pfizer, Qpex, Satsuma, Targovax, Tarsus, Viking.
Artios Pharma Ltd. plans to begin the first clinical trials of a POLQ inhibitor class cancer drug later this year. There are a handful of companies working on POLQ inhibitor drugs, the name of the gene that encodes the enzyme DNA polymerase theta, but it looks like Artios has taken a head start following the publication of the supportive study in Nature Communications.
Livanova plc has launched an IDE trial of its Aura6000 sleep apnea device, following approval by the FDA to proceed with the study. The implantable pulse generator (IPG) is designed to treat patients with moderate to severe obstructive sleep apnea (OSA) who do not get relief from a traditional continuous positive airway pressure (CPAP) machine or refuse to use one.
LONDON – Curevac NV blamed the high number of circulating SARS-CoV-2 variants after its COVID-19 vaccine failed to meet the primary endpoint in the interim analysis of the phase IIb/III trial. The vaccine, Cvncov, was only 47% effective in preventing COVID-19 infections in the 40,000-person study.
While phase I-III clinical trial data continue to rise above the same timeframe in 2020, the gap is closing and a smaller percentage of this year’s reports are focused on the COVID-19 pandemic.
LONDON – Regeneron Pharmaceuticals Inc.’s antibody cocktail, Regen-Cov, has been shown to significantly reduce mortality in seriously ill hospitalized COVID-19 patients who have failed to mount their own immune response against the SARS-CoV-2 virus. Among these seronegative patients, the casirivimab/imdevimab monoclonal antibody mixture reduced deaths by 20% (p=0.001) in the U.K. Recovery trial.
RSS
